Click (NASDAQ:CLIK) Upgraded to “Hold” at Wall Street Zen

Click (NASDAQ:CLIK) was upgraded by analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Click in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Click Stock Performance

Click stock opened at $1.58 on Friday. The business has a 50 day simple moving average of $2.12 and a 200-day simple moving average of $3.60. Click has a 12 month low of $1.32 and a 12 month high of $15.90.

Click (NASDAQ:CLIK) last announced its earnings results on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The company had revenue of $3.79 million during the quarter.

Institutional Investors Weigh In On Click

An institutional investor recently bought a new position in Click stock. Renaissance Technologies LLC bought a new stake in Click Holdings Limited (NASDAQ:CLIK) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned about 1.23% of Click as of its most recent SEC filing.

Click Company Profile

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.